Kristie L. Kahl

The Food and Drug Administration approved Imbruvica plus Gazyva for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

In this week’s episode of CURE Talks Cancer, we spoke with two doctors honored for their efforts to improve the quality of life for those affected by chronic lymphocytic leukemia (CLL).

23andMe received Food and Drug Administration (FDA) clearance for a genetic health risk report on a hereditary colorectal cancer syndrome, according to the genetics company.

A man with glioblastoma has received Gliovac (ERC1671) under legislation allowing for the terminally ill to try experimental drugs that have passed preliminary FDA testing.

Older adults may be at an increased risk for a heart attack or stroke five months before they are even diagnosed with cancer – a risk that peaked in the month prior to diagnosis, according to a report published in Blood.

A recent survey demonstrated the common tradeoffs most patients report regarding treatment decisions, highlighting the importance of shared decision making.

The Food and Drug Administration has accepted Roche’s supplemental biologics license application for Tecentriq (atezolizumab) plus chemotherapy for the frontline treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.

The Food and Drug Administration approved Cabometyx (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib).

This week, we spoke with the co-founder of a nonprofit organization dedicated to funding research to eliminate childhood cancer, as well as two families who have benefitted from the research being done in this area.

The Raymond Foundation released the Cancer Caregiver Action Plan to help others with emotional support and information.

In an interview with CURE, Filippo Milano, M.D., Ph.D., explains what cord blood transplantation is and why it is important for patients to learn more.

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

The Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients aged 2 or older.

The Food and Drug Administration (FDA) granted accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to the agency.

The combination use of Imbruvica (ibrutinib) with Rituxan (rituximab) significantly improved survival outcomes compared with standard of care in younger patients with chronic lymphocytic leukemia (CLL).

Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).

Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.

This week, we spoke with three sisters with a long family history of the BRCA gene mutation – one that dates back to 1860 in Poland.

The combination of Darzalex (daratumumab), Revlimid (lenalidomide) and dexamethasone significantly reduced the risk for disease progression in patients with newly diagnosed multiple myeloma.

This week, we spoke with former NFL coach, motivational speaker and acute promyelocytic leukemia survivor Chuck Pagano about his journey with cancer, and what has inspired him to give back following his diagnosis.

Long-term follow-up of the JULIET trial showed patients with relapsed or refractory DLBCL continued to experience durable responses 19 months after treatment.

Treatment with Xarelto (rivaroxaban) may reduce the risk for developing blood clots during active treatment with a systemic therapy like chemotherapy, according to results from the CASSINI trial.

The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

While the treatment landscape continues to grow in bladder cancer, researchers should continue to follow the evidence, but accrual of patients in clinical trials is also key, according to Petros Grivas, M.D., Ph.D.

In this episode, we spoke with a mother-daughter advocacy duo who has set out to help other families facing a cancer journey.

Despite associated toxicities, cisplatin chemotherapy induced superior efficacy compared with a new alternative among patients with HPV-positive oropharyngeal carcinoma.

The treatment paradigm for bladder cancer has been quite exciting in the last few years, and even more is yet to come, according to Petros Grivas, M.D., Ph.D.

To receive payment for counseling and increase access to services, a new bill has been introduced so that genetic counselors receive payment for counseling Medicare beneficiaries.

Patients who received chemotherapy, actively smoked and drank alcohol, and were diagnosed with head and neck cancer reported significantly higher rates of opiate use, according to study results presented at the American Society of Clinical Oncology (ASCO) 2018 Palliative and Supportive Care Symposium.

A Danish study demonstrated smokers were 2.5 times more likely to develop a myeloproliferative neoplasm compared with their non-smoking counterparts.